Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 828,426
  • Shares Outstanding, K 47,150
  • Annual Sales, $ 1,540 K
  • Annual Income, $ -135,750 K
  • 36-Month Beta 0.98
  • Price/Sales 538.17
  • Price/Cash Flow 0.00
  • Price/Book 14.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.90 +17.92%
on 08/23/17
17.83 -1.46%
on 09/21/17
+2.53 (+16.82%)
since 08/22/17
3-Month
12.78 +37.48%
on 08/02/17
17.83 -1.46%
on 09/21/17
+1.08 (+6.55%)
since 06/22/17
52-Week
7.16 +145.39%
on 11/03/16
17.83 -1.46%
on 09/21/17
+8.32 (+89.95%)
since 09/22/16

Most Recent Stories

More News
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

AKBA : 17.57 (+0.29%)
BMRN : 94.95 (+1.64%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down

GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.

AKBA : 17.57 (+0.29%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
GTXI : 8.76 (+0.23%)
Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

RARE : 52.16 (-0.69%)
AKBA : 17.57 (+0.29%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
Stocks Under Scanner in the Biotech Space -- Acorda Therapeutics, Advaxis, Xbiotech, and Akebia Therapeutics

If you want a Stock Review on ACOR, ADXS, XBIT, or AKBA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, September 08, 2017, the NASDAQ...

ADXS : 4.57 (-3.38%)
AKBA : 17.57 (+0.29%)
ACOR : 23.45 (-0.64%)
XBIT : 4.19 (-4.56%)
BioMarin Presents Interim Data on BMN 250 from Phase I/II

BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.

AKBA : 17.57 (+0.29%)
BMRN : 94.95 (+1.64%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge

Akebia Therapeutics (AKBA), could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

AKBA : 17.57 (+0.29%)
Akebia to Present at Upcoming Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

MS : 48.22 (-0.08%)
AKBA : 17.57 (+0.29%)
FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down

Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.

AKBA : 17.57 (+0.29%)
ACOR : 23.45 (-0.64%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
Strength Seen in Catalent (CTLT): Stock Soars 13.9%

Catalent (CTLT) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.

CTLT : 40.76 (+1.29%)
AKBA : 17.57 (+0.29%)
Adamas Pharmaceu has the Best Relative Performance in the Biotechnology Industry (ADMS, ACOR, ESPR, AKBA, EPZM)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ESPR : 49.31 (-0.12%)
ADMS : 21.37 (+0.23%)
AKBA : 17.57 (+0.29%)
ACOR : 23.45 (-0.64%)
EPZM : 16.95 (-9.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Support & Resistance

2nd Resistance Point 17.95
1st Resistance Point 17.76
Last Price 17.57
1st Support Level 17.42
2nd Support Level 17.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.